grant
Elucidating the Role of the Thousand and One Kinases in Retinal Ganglion Cell Death
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 19 May 2025Deadline 18 May 2029
NIHUS FederalResearch GrantFY2025AchievementAchievement AttainmentAd vectorAdeno-Associated VirusesAdenoviral VectorAdenoviridaeAdenovirus VectorAdenovirusesAntimorphic mutationAssayAttenuatedAxonBioassayBiological AssayBlindnessBody TissuesC-jun Amino-Terminal KinaseC-jun Kinase-1C-jun N-Terminal Kinase 1CRISPRCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas systemCRISPR/Cas9 screenCell BodyCell Communication and SignalingCell Culture TechniquesCell DeathCell Death SignalingCell Death Signaling ProcessCell SignalingCell SurvivalCell ViabilityCellsClustered Regularly Interspaced Short Palindromic RepeatsColchicineComplementary DNACore FacilityCranial Nerve IICranial Nerve II DiseasesCranial Nerve II DisorderDataDependoparvovirusDependovirusDerivationDerivation procedureDominant NegativeDominant-Negative MutantDominant-Negative MutationGenesGlaucomaGoalsHigh Throughput AssayHistologicHistologicallyHumanIn VitroInjuryIntracellular Communication and SignalingIntraocular PressureInvestigationJN KinaseJNKJNK Mitogen-Activated Protein KinasesJNK1JNK1 KinaseJNK1 proteinJNK1A2JNK21B1/2JUNKinasesKnock-outKnockoutLeucine ZippersMAP Kinase 8MAP Kinase 8 GeneMAPK8MAPK8 Mitogen-Activated Protein KinaseMAPK8 geneMaintenanceMeasuresMediatingMediatorMiceMice MammalsMitogen-Activated Protein Kinase 8ModelingModern ManMorphologyMurineMusN-terminalNH2-terminalNerve CrushNeural-Optical LesionOcular TensionOptic NerveOptic Nerve DiseasesOptic NeuropathyPRKM8ParticipantPathway interactionsPatientsPhasePhosphorylationPhosphotransferase GenePhosphotransferasesPhysiciansPhysiologic Intraocular PressurePrincipal InvestigatorProductionProtein PhosphorylationRNA SeqRNA sequencingRNAseqRegulationRetinaRetinal Ganglion CellsRodentRodent ModelRodentiaRodents MammalsRoleS. pyogenesSAP Kinase-1SAPK/JNKSAPK1 Mitogen-Activated Protein KinaseSAPK1/JNKScientistSecond Cranial NerveSecond Cranial Nerve DiseasesSignal PathwaySignal TransductionSignal Transduction SystemsSignalingStreptococcus Group AStreptococcus pyogenesStress-Activated Protein Kinase JNK1Stress-Activated Protein Kinase gammaSupervisionSurfaceTestingTissuesTrainingTransphosphorylasesViralWorkadeno associated virus groupadeno vectoradenovectorattenuateattenuatesaxon damageaxon injuryaxonal damageaxonal injurybiological signal transductionc-jun N-Terminal KinasecDNAcareercell culturecell culturesclustered regularly interspaced short palindromic repeats screendifferential expressiondifferentially expresseddirected differentiationfunctional genomicsgain of functiongene functiongene manipulationgenetic manipulationgenetically manipulategenetically perturbglaucomatousglobal gene expressionglobal transcription profilegroup A strephigh throughput screeninghuman modelhuman progenitorhuman progenitor cell derivedhuman stem cell-derivedhuman stem cellsiPSiPSCiPSCsimmunocytochemistryin vitro Modelin vivoinduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinjuriesintra-ocular pressurejun Oncogenejun-NH2-Terminal Kinaseloss of functionmembermodel of humanmouse modelmurine modelnecrocytosisnerve cell deathnerve cell lossneuron cell deathneuron cell lossneuron deathneuron lossneuronal cell deathneuronal cell lossneuronal deathneuronal lossneuroprotectionneuroprotectivenoveloptic nerve disorderparalogparalogous genepathwaypharmacologicprogenitor cell differentiationprogenitor differentiationresponseretinal ganglionsecond cranial nerve disorderskillssocial rolestem and progenitor differentiationstem cell differentiationstress-activated protein kinase 1therapeutic targettooltranscriptional differencestranscriptometranscriptome sequencingtranscriptomic sequencingvectorvision lossvisual loss
Description preview
Abstract
Glaucoma causes irreversible, progressive vision loss via axon injury and subsequent cell death of retinal
ganglion cells (RGCs). Current treatments aim to lower intraocular pressure, although this is insufficient in some
patients and associated with complications in others. As such, it is proposed herein to develop complementary…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click